JANX
Janux Therapeutics Inc.
$27.01
-$0.36(-1.32%)
63
Overall
60
Value
66
Tech
63
Quality
Market Cap
$1.59B
Volume
1.39M
52W Range
$21.73 - $71.71
Target Price
$81.20
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $3.6M | $8.6M | $8.1M | $10.6M | ||
| Total Revenue | $3.6M | $8.6M | $8.1M | $10.6M | ||
| GROSS PROFIT | ||||||
| Gross Profit | $3.6M | $8.6M | $8.1M | $10.6M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $36.6M | $75.7M | $81.1M | $109.4M | ||
| Research & Development | $26.2M | $53.4M | $54.9M | $68.4M | ||
| Research Expense | $26.2M | $53.4M | $54.9M | $68.4M | ||
| Selling, General & Administrative | $10.3M | $22.3M | $26.1M | $41.0M | ||
| General & Administrative Expenses | $10.3M | $22.3M | $26.1M | $41.0M | ||
| Salaries & Wages | $6.9M | $17.2M | $20.0M | $33.0M | ||
| Other Operating Expenses | $-326.0K | $-763.0K | $-990.0K | $-1.6M | ||
| OPERATING INCOME | ||||||
| Operating income | $-32.9M | $-67.1M | $-73.0M | $-98.8M | ||
| EBITDA | $-32.7M | $-66.0M | $-59.2M | $-70.4M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $257.0K | $4.0M | $14.7M | $29.9M | ||
| Net Non-Operating Interest Income/Expense | $257.0K | $4.0M | $14.7M | $29.9M | ||
| Other Income/Expense | $-300.0K | $-200.0K | $-2.8M | $-3.4M | ||
| Other Special Charges | $300.0K | $200.0K | $2.8M | $3.4M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-32.7M | $-66.8M | $-61.1M | $-72.4M | ||
| Pre-Tax Income | $-32.7M | $-63.1M | $-58.3M | $-69.0M | ||
| INCOME TAX | ||||||
| Tax Provision | $-2.2M | $-3.8M | $-2.8M | $-3.4M | ||
| NET INCOME | ||||||
| Net Income | $-32.7M | $-63.1M | $-58.3M | $-69.0M | ||
| Net Income (Continuing Operations) | $-32.7M | $-63.1M | $-58.3M | $-69.0M | ||
| Net Income (Discontinued Operations) | $-32.7M | $-63.1M | $-58.3M | $-69.0M | ||
| Net Income (Common Stockholders) | $-32.7M | $-63.1M | $-58.3M | $-69.0M | ||
| Normalized Income | $-34.8M | -- | -- | $-72.4M | ||
| TOTALS | ||||||
| Total Expenses | $36.6M | $75.7M | $81.1M | $109.4M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $23.5M | $41.5M | $44.0M | $53.8M | ||
| Average Shares Outstanding (Diluted) | $23.5M | $41.5M | $44.0M | $53.8M | ||
| Shares Outstanding | $41.6M | $41.8M | $51.7M | $59.1M | ||
| Basic EPS | $-1.39 | $-1.52 | $-1.32 | $-1.28 | ||
| Basic EPS (Continuing Operations) | $-1.39 | $-1.52 | $-1.32 | $-1.28 | ||
| Diluted EPS | $-1.39 | $-1.52 | $-1.32 | $-1.28 | ||
| Diluted EPS (Continuing Operations) | -- | $-1.52 | $-1.32 | $-1.28 | ||
| OTHER METRICS | ||||||
| Other Gand A | $10.3M | $22.3M | $26.1M | $41.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JANX | $27.01 | -1.3% | 1.39M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |